604 Results for "

SCO2 mutations

" in MedChemExpress (MCE) Product Catalog:
Products (604)

604 Results for "SCO2 mutations" in MCE Product Catalog:

Cat. No.: HY-131597
CAS No.: 21238-36-8
Synonyms: 8-Hydroxyguanosine triphosphate
Research Areas:  

Infection Cancer

8-Oxo-GTP (8-Hydroxyguanosine triphosphate) is an oxidized guanine nucleotide, produced by reactive oxygen species (ROS). 8-Oxo-GTP serves as a substrate for MutT protein, GTP cyclohydrolase II, Mycobacterium tuberculosis MutT1, and Mycobacterium tuberculosis Rv1700, which hydrolyze it to corresponding nucleoside monophosphates or diphosphates. 8-Oxo-GTP causes detrimental effects including mutations and mistranslation when incorporated into nucleic acids. 8-Oxo-GTP can be used for the research of cancer and tuberculosis [2] .
loading...
    loading...
Cat. No.: HY-136881
CAS No.: 954371-52-9
Target:  

CCR

Research Areas:  

Inflammation/Immunology

CH0076989 is a specific CCR3 agonist. CH0076989 activates eosinophils and transfectants expressing both wild-type CCR3 and a CCR1:CCR3 chimaeric receptor lacking the CCR3 amino-terminus. CH0076989 has a direct interaction with the transmembrane helices of CCR3, supported by the complete loss of its activity due to mutations of the residues Y41, Y113 and E287. CH0076989 can be used for the study of inflammation and allergic diseases (such as asthma) .
loading...
    loading...
Cat. No.: HY-148260
CAS No.: 2648221-12-7
Target:  

Ras

Research Areas:  

Cancer

KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC50 value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .
loading...
    loading...
Cat. No.: HY-155246
Target:  

Apoptosis PARP

Research Areas:  

Cancer

PARP1-IN-15 (Compound 6) is a PARP1 inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations .
loading...
    loading...
Cat. No.: HY-156632
CAS No.: 2750709-91-0
Purity:  99.53%
Synonyms: KIN-3248
Target:  

FGFR

Research Areas:  

Cancer

Resigratinib (KIN-3248) is an irreversible and orally active covalent inhibitor of FGFR1-4 that effectively inhibits wild-type and drug-resistant mutations (such as FGFR2 V565F, FGFR3 V555M). Resigratinib covalently binds to the Cys492 site of FGFR, blocks the FGFR signaling pathway, inhibits tumor cell proliferation and induces apoptosis. Resigratinib can be used for the study of FGFR2/3-driven solid tumors (such as cholangiocarcinoma and bladder cancer) [2].
loading...
    loading...
Cat. No.: HY-162299
CAS No.: 2922402-03-5
Target:  

EGFR

Research Areas:  

Cancer

EGFR kinase inhibitor 3 (compound 2) is a bivalent ATP-allosteric EGFR kinase inhibitor with IC50s of <10 nM, 1.5 nM, 0.059 nM, 0.064 nM for WT EGFR, EGFR-activating mutations L858R, L858R/T790M and L858R/T790M/C797S, respectively. EGFR kinase inhibitor 3 is a C-linked inhibitor .
loading...
    loading...
Cat. No.: HY-16662
CAS No.: 75629-57-1
Research Areas:  

Cancer

Oncrasin-1 is an RNA polymerase inhibitor. Oncrasin-1 suppresses the phosphorylation of the largest subunit of RNA polymerase II and the expression of intronless reporter genes in sensitive cells. Oncrasin-1 effectively kills various human lung cancer cells with K-Ras mutations. Oncrasin-1 leads to coaggregation of PKCι and splicing factors into megaspliceosomes. Oncrasin-1 induces malfunction in the RNA processing machinery. Oncrasin-1 is an anti-cancer agent and can therefore be studied in research for lung cancer [2].
loading...
    loading...
Cat. No.: HY-169148
Research Areas:  

Cancer

YT117R is a PROTAC degrader targeting BRD4. YT117R binds stereoselectively and site-specifically to the cysteine residue C1113 of DCAF1 to form a covalent interaction. YT117R promotes BRD4 degradation via a DCAF1-dependent, proteasome- and cullin-RING E3 ligase-mediated process. YT117R exhibits stereoselective activity dependent on wild-type DCAF1, which is blocked by the DCAF1 C1113A mutation .
loading...
    loading...
Cat. No.: HY-172429
CAS No.: 2489185-38-6
Synonyms: ORIC-114
Target:  

EGFR

Research Areas:  

Neurological Disease Cancer

Enozertinib (ORIC-114) is an orally active, CNS-penetrant, highly selective and irreversible dual EGFR/HER2 inhibitor that exhibits potent and targeted inhibition of exon 20 insertion mutations. Enozertinib exhibits high kinome selectivity for the EGFR family of receptors to reduce off-target kinase liabilities. Enozertinib induces tumor regression and demonstrates antitumor activity in central nervous system and non-small cell lung cancer (NSCLC) tumor models. Enozertinib can be used for the research of solid tumors and NSCLC [2].
loading...
    loading...
Cat. No.: HY-172429A
Synonyms: ORIC-114 hemihydrate
Target:  

EGFR

Research Areas:  

Neurological Disease Cancer

Enozertinib (ORIC-114) hemihydrate is an orally active, CNS-penetrant, highly selective and irreversible dual EGFR/HER2 inhibitor that exhibits potent and targeted inhibition of exon 20 insertion mutations. Enozertinib hemihydrate exhibits high kinome selectivity for the EGFR family of receptors to reduce off-target kinase liabilities. Enozertinib hemihydrate induces tumor regression and demonstrates antitumor activity in central nervous system and non-small cell lung cancer (NSCLC) tumor models. Enozertinib hemihydrate can be used for the research of solid tumors and NSCLC [2] .
loading...
    loading...
Cat. No.: HY-174261
CAS No.: 3082412-00-5
Target:  

Ras

Research Areas:  

Cancer

KRAS-IN-5 (Compound Ex 6) is an orally active and selective inhibitor targeting KRAS mutants (including KRAS G12D, KRAS G12V, KRAS WT) with a GNE IC50 value of 1.3 nM against KRAS G12D. KRAS-IN-5 blocks tumor cell proliferation by inhibiting KRAS-mediated signaling pathways (e.g., reducing ERK phosphorylation). KRAS-IN-5 is promising for research of KRAS mutation-related cancers, such as pancreatic cancer, colorectal cancer, lung cancer .
loading...
    loading...
Cat. No.: HY-174887
CAS No.: 2920045-74-3
THR-β agonist 9 is a potent, selective, and His435 mutation-sensitive THR-β (EC50: 3.2 nM) agonist. THR-β agonist 9 has moderate selectivity (approximately 10-fold) and good activation capacity (EC50: 134.2 nM to 515.5 nM) for multiple His435 mutants (H435A, H435Y, and H435R). THR-β agonist 9 has the potential to be used in the study of dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), or resistance to thyroid hormone (RTH) .
loading...
    loading...
Cat. No.: HY-179300
CAS No.: 3074833-86-3
Target:  

Ras

Research Areas:  

Cancer

KRAS-IN-48 free base (Compound 1-01) is a mutant KRAS inhibitor, with Kd values of 2.58 nM and 5.49 μM for KRAS G12D and KRAS G12V, respectively. KRAS-IN-48 free base affects pERK expression in cells harboring KRAS G12D and KRAS G12V mutations, with IC50 values of 1.1 μM and 1.51 μM, respectively. KRAS-IN-48 free base can be used in the research of cancer .
loading...
    loading...
Cat. No.: HY-180969
CAS No.: 2378581-37-2
Target:  

PROTACs Bcr-Abl

Research Areas:  

Cancer

SIAIS056 is a BCR-ABL PROTAC degrader with a DC50 value of 0.18 nM. SIAIS056 time-dependently inhibits the BCR-ABL signaling pathway, accompanied by decreased phosphorylation of BCR-ABL and the downstream molecules STAT5 and CRKL in K562 cells. SIAIS056 induces the degradation of several clinically relevant resistance-conferring mutations of BCR-ABL. SIAIS056 exhibits anti-proliferative activity and induces substantial tumor regression in K562 xenograft models. SIAIS056 can be used for leukemia research [2].
loading...
    loading...
Cat. No.: HY-183574
Target:  

Parasite

Research Areas:  

Infection

Antimalarial agent 62 is an orally active imidazopyridine-6-carboxamide antimalarial agent with a high resistance barrier. Antimalarial agent 62 kills trophozoite-stage Plasmodium ring forms, effectively clears dihydroartemisinin-induced dormant Plasmodium ring forms, and eliminates parasitemia in mice infected with Plasmodium yoelii. In AReBaR resistance omics screening, Antimalarial agent 62 is not affected by different target- and efflux-mediated resistance mutations and can withstand resistance selection. Antimalarial agent 62 has been applied to studies of malaria-related mechanisms .
loading...
    loading...
Cat. No.: HY-183682
CAS No.: 3101563-22-5
Target:  

EGFR p38 MAPK ERK Akt

Research Areas:  

Cancer

AZ14289671 is an orally active, blood-brain barrier-penetrant tyrosine kinase (tyrosine kinase) inhibitor (TKI) that specifically targets non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations (EGFR Exon20Ins), while largely sparing wild-type EGFR to reduce off-target toxicities such as rash and diarrhea. AZ14289671 inhibits the downstream MAPK/ERK/AKT pathway, suppressing tumor cell proliferation, survival and migration. AZ14289671 can be used for NSCLC research .
loading...
    loading...
Cat. No.: HY-19895
CAS No.: 1356918-39-2
Target:  

Bacterial

Research Areas:  

Infection

DS-8587 is a new fluoroquinolone with significant antibacterial activity. The MIC value of DS-8587 against clinically isolated amoxicillin-resistant Bacillus strains is superior to ciprofloxacin and levofloxacin. The antibacterial activity of DS-8587 is less affected by adeA/adeB/adeC or abeM efflux pumps, and has more advantages than ciprofloxacin. DS-8587 has a lower single-step mutation frequency than ciprofloxacin. DS-8587 may be an effective drug for inhibiting amoxicillin-resistant Bacillus infections .
loading...
    loading...
Cat. No.: HY-51424S
CAS No.: 1304096-50-1
PLX-4720-d7 is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of?B-RafV600E?with?an IC50?of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf [2].
loading...
    loading...
Cat. No.: HY-N2533R
CAS No.: 33012-73-6
Synonyms: Cyanidin-3-O-sambubioside chloride (Standard)
Cyanidin 3-sambubioside (chloride) (Standard) is the analytical standard of Cyanidin 3-sambubioside (chloride). This product is intended for research and analytical applications. Cyanidin 3-sambubioside chloride (Cyanidin-3-O-sambubioside chloride), a major anthocyanin, a natural colorant, and is a potent NO inhibitor. Cyanidin 3-sambubioside chloride is a H274Y mutation inhibitor, and inhibits influenza neuraminidase activity with an IC50 of 72 μM. Cyanidin 3-sambubioside chloride inhibits angiotensin-converting enzyme (ACE) activity and has antioxidant, anti-angiogenic and antiviral properties [2] .
loading...
    loading...
Cat. No.: HY-P990936
CAS No.: 2823332-50-7
Synonyms: JYB-1904; RPT904
Target:  

Others

Research Areas:  

Inflammation/Immunology

Ozureprubart (JYB-1904; RPT904) is an anti-IgE humanized monoclonal antibody. Ozureprubart blocks the binding of IgE to FcαRI and dissociates bound IgE by binding free immunoglobulin E (IgE), while reducing receptor-bound IgE and FcαRI on basophils. The antibody carries a YTE mutation in the Fc fragment to extend serum half-life and has modifications that increase IgE binding affinity, improve stability, and reduce immunogenicity potential, and it can be used for research on allergic asthma, chronic spontaneous urticaria, and allergic inflammatory diseases [2].
loading...
    loading...